MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. - Wikidata - awgldk - TriplyDB

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

http://www.wikidata.org/entity/Q34775393

about

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis Genomic landscape of megakaryopoiesis and platelet function defects Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management JAK2 activation by growth hormone and other cytokines JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 Novel therapies for myelofibrosis The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control Thrombopoietin and hematopoietic stem cells.2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and T WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis AKT is a therapeutic target in myeloproliferative neoplasms Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms.Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms.CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms.An MPL W515L mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis: A case report.How I treat essential thrombocythemia.The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.Low frequency of c-MPL gene mutations in Iranian patients with Philadelphia-negative myeloproliferative disorders.Emerging treatments for essential thrombocythemia Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia.

P2860

Q21285040-4ED21983-389B-4F53-BD95-72436D48BCB8 Q24607513-84F9E7B0-D283-4BE1-AEEE-AF36E2DE077E Q24631288-8711030C-8396-4B95-AF5C-0C6E4526A9B5 Q26752940-327715AF-8DD7-4DFB-B40E-79B7D03047D7 Q26770330-84194B28-D7E8-44B7-817B-8ABD0FC2283C Q26770869-9DB2820A-F512-43C7-A358-3BC558B455D4 Q26777265-14308A67-1432-4755-8845-193FF0247B16 Q26851894-31933C6B-6347-4163-835C-EA1DE5197E69 Q27003058-0DBFDA78-D196-4D1C-A407-DA9856D3C261 Q27012572-A5D83348-814E-4F53-A632-6A0405F1ABA7 Q27687464-703797AA-EACF-4F1D-A692-88A5FFC1DB5D Q28081693-72F9A1CF-E963-4515-A032-BAF82FBD2E0F Q28082685-AF6AD45A-CD35-4ADF-8495-A8FF0C6967B8 Q33394846-C345D56F-1947-4484-ADD0-4A66F7B6D85E Q33572605-71F2E093-F278-4F34-BD90-617B4AF064A8 Q33581974-2E4296CF-60E0-4E6C-B195-F3A3A6078788 Q33587677-8939A767-5EFD-4B02-BB83-4037207BC565 Q33623277-6A40EA01-E7B1-476E-80FF-714DDC122415 Q33788714-457D4A16-41A9-472A-ABCF-6FAF0E76C6EC Q33982315-FE331D79-AC99-4F31-AE06-B61B05976EE6 Q34150008-5409905A-AE1D-4D91-8674-E3E893507B9A Q34162151-3FACF309-F178-4364-8ED7-A3598ADB5E46 Q34166859-5B69726F-482F-4BC9-A256-7ADA524D3D0D Q34302770-849F5886-136D-47DB-AB0D-49A23B0C721A Q34370771-BBFE04F8-BC9E-4E1E-BE71-D491BB98B8B1 Q34417810-37A225B7-3423-4BD3-A407-65635CF34A2F Q34451630-D29F693D-6000-43E7-B642-2399DB64A3F1 Q34467863-B1BB1C8A-986B-4BF2-8A7A-153A7804D47A Q34485103-688E4C31-67DF-4E03-B66E-A0BFC10EC808 Q34575726-F2A799A2-2290-4B47-BAF7-4F90833C73DB Q34612586-D71CAF29-BCA0-4E6C-BDC4-BD90EB20283A Q34750599-B30435C0-4893-4261-ABF4-02D41B622F00 Q34993654-BE5D1874-5E34-44B0-8B42-B54901054168 Q35132271-6662CF02-3F69-4AC0-BDA7-50755340BD72 Q35132280-3BA07605-8755-4651-924E-99B52D5758C4 Q35433259-0856A4C5-A3FF-41E8-AC76-25F614885FE9 Q35470697-203A6399-131E-41DC-8EEC-904200473B00 Q35683853-9DCFA41F-F5CC-42CB-861E-FBA6C7E4C12C Q36001930-67D56545-72A8-4B57-9457-131C843BBC23 Q36072642-4EE1F680-E288-4AE5-9FB8-9C319B83CCF1

P2860

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

http://www.wikidata.org/entity/Q34775393

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

@ast

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

@en

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

@nl

type

label

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

@ast

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

@en

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

@nl

prefLabel

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

@ast

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

@en

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

@nl

P1433

Q34775393-774A50B8-F785-4B4C-9AC2-94389FF86DA8

P1476

Q34775393-AD0D2FBC-831D-4525-ABB1-E59D112E034B

P2093

Q34775393-5F3DF834-42C2-4407-965C-68C177876938

Q34775393-7297FECB-CFA2-485D-BF7A-7776F7FB1B10

Q34775393-88C6CCAC-A4AC-4C4B-9899-21F97C76D895

Q34775393-8BCDE1D2-D82C-4C5E-848B-75AA96259F71

Q34775393-A6A1E7F4-2531-4000-A2D2-2FB630F53DC2

Q34775393-A834FB0F-12E9-429F-9FC5-A3BF7B34B9E1

Q34775393-B7E5630D-0511-450E-A82B-DAE2DD360ABE

Q34775393-CA6C5BEE-77EC-4D92-8289-8CD94F06DDD5

Q34775393-D0FBEC9C-F54B-4D43-AA14-9001CEB0BD51

P304

Q34775393-F614A792-227F-49B8-A384-6CC04DE275BC

P31

Q34775393-6E19E182-8465-4A7E-BCDF-4F37868CA5F2

P356

Q34775393-E5665DBE-5DA3-4126-AC55-CCBA3DAA736F

P407

Q34775393-187C8CB9-C958-4B2B-99E6-50F6001A568B

P433

Q34775393-F6FB7613-2CD2-44C5-A272-5660D2E9C0D5

P478

Q34775393-9E40BFA3-2D1A-4EDF-9DA4-4CE1B9A20603

P50

Q34775393-0D4D03BA-FB67-48EA-B1B9-B15C4D2B2FD6

Q34775393-4511BE54-73F1-48EC-BB59-C3BA71575FC0

Q34775393-7FCD5303-D8A7-4D3C-A5DA-E53B848688D4

Q34775393-9B6A5127-FE7C-4D98-B11C-D8AC1E4721AD

Q34775393-9E7AEBD0-3248-4383-B030-3FFDF7DFB435

P577

Q34775393-CF275A04-E2FD-42C7-BCD6-98A8A43A5D7C

P5875

Q34775393-0937B8E7-A7C6-4848-98CF-A9A1539301C9

P698

Q34775393-F54C2887-C01C-4DE5-B248-B824925D1023

P356

BLOOD-2008-01-131664

P1433

P1476

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

@en

P2093

Anthony J Bench

http://www.w3.org/2001/XMLSchema#string

Bridget S Wilkins

http://www.w3.org/2001/XMLSchema#string

Claire N Harrison

http://www.w3.org/2001/XMLSchema#string

David Bareford

http://www.w3.org/2001/XMLSchema#string

John T Reilly

http://www.w3.org/2001/XMLSchema#string

Keith Wheatley

http://www.w3.org/2001/XMLSchema#string

Peter J Campbell

http://www.w3.org/2001/XMLSchema#string

Philip A Beer

http://www.w3.org/2001/XMLSchema#string

Richard Bowman

http://www.w3.org/2001/XMLSchema#string

P304

141-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-01-131664

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Hans K. Hasselbalch

Anthony R Green

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5332408

http://www.w3.org/2001/XMLSchema#string

P698

18451306

http://www.w3.org/2001/XMLSchema#string